Document is current
Any future updates will be listed below
-
Authors
Granroth, Ginna https://orcid.org/0000-0003-3679-8272
Rosenthal, Allison
McCallen, Maggie
Coughlin, Christopher
Benson, Hollie
Palmer, Jeanne
Castro, Januario E.
Munoz, Javier
- License Information
-
More Information
Article History
Accepted: 5 July 2022
First Online: 7 November 2022
Declarations
:
: GG Consulting—Strategix, The Lynx Group, Incyte, CTI BioPharma.JM Consulting—Pharmacyclics/Abbvie, Bayer, Gilead/Kite Pharma, Pfizer, Janssen, Juno/Celgene, BMS, Kyowa, Alexion, Fosunkite, Innovent, Seattle Genetics, Debiopharm, Karyopharm, Genmab, ADC Therapeutics, Epizyme, Beigene, Servier, Novartis, Morphosys/Incyte; Research funding—Bayer, Gilead/Kite Pharma, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium. Honoraria from Targeted Oncology, OncView, Curio, Kyowa, Physicians Education Resource, and Seattle Genetics; Speaker’s bureau—Gilead/Kite Pharma, Kyowa, Bayer, Pharmacyclics/Janssen, Seattle Genetics, Acrotech/Aurobindo, Beigene, Verastem, AstraZeneca, Celgene/BMS, Genentech/Roche. JEC Consulting—FATE therapeutics, Kite Pharmaceuticals.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
